PTO-1449 REPRODUCED

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION

November 16, 2004

(Use several sheets if necessary)

ATTORNEY DOCKET NO.	APPLICATION NO.
2629.1003-008	10/820,478
FIRST NAMED INVENTOR	**FILING DATE**
Sudhir V. Shah	April 8, 2004
EXAMINER	**CONFIRMATION NO.** / **GROUP**
Not Assigned	8698 / 1654

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AK	US 2003/0064929 A1	04/03/2003	Duranton *et al.*

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	TRANSLATION NO
	AL2	WO 90/04584	05/03/1990	BIOREX KUTATO FEJLESZTO KFT.		

EXAMINER	DATE CONSIDERED
	02/28/2005

PTO-1449 REPRODUCED

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION

August 31, 2004

(Use several sheets if necessary)

ATTORNEY DOCKET NO.	APPLICATION NO.
2629.1003-008	10/820,478
FIRST NAMED INVENTOR	**FILING DATE**
Sudhir V. Shah	April 8, 2004
EXAMINER	**CONFIRMATION NO.** / **GROUP**
Not Assigned	8698 / 1654

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AE	4,684,482	08-04-1987	Green
	AF	5,047,329	09-10-1991	Suzuki
	AG	6,206,849 B1	03-27-2001	Martin *et al.*
	AH	6,383,817 B2	05-07-2002	Schwartz
	AJ	6,589,966 B1	07-08-2003	Torti *et al.*
	AJ	6,706,287 B2	03-16-2004	Ranganathan *et al.*

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	TRANSLATION NO
	AP	WO 00/54784	09-21-2000	Aripkohodzhaeva		X
	AQ	JP 05000949 A	01-08-1993	Santen Pharmaceuticals Co., Ltd Dai Ichi Seiyaku Co., Ltd.	X (Abstract)	

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AW5	Fernández-Real, J.M., *et al.*, "Cross-Talk Between Iron Metabolism and Diabetes," *Diabetes, 51*:2348-2354, 2002
	AX5	Nitenberg, A., *et al.*, "Coronary Microvascular Adaptation to Myocardial Metabolic Demand Can Be Restored by Inhibition of Iron-Catalyzed Formation of Oxygen Free Radicals in Type 2 Diabetic Patients," *Diabetes, 51*:813-818, 2002

EXAMINER [signature] DATE CONSIDERED 07/28/2005

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION **April 8, 2004** (Use several sheets if necessary)	2629.1003-008 FIRST NAMED INVENTOR Sudhir V. Shah

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	TRANSLATION NO
dw	AP	WO 88/04925	07-14-1988	The Administrators of the Tu-Lane Educational Fund		
w	AQ	WO 98/09626	03-12–1998	Medinox, Inc.		

EXAMINER	DATE CONSIDERED
	02/13/2007

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2629.1003-008
April 8, 2004	FIRST NAMED INVENTOR Sudhir V. Shah
(Use several sheets if necessary)	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AA	5,047,421	09-10-91	Green
	AB	5,721,209	02-24-98	Horwitz *et al.*
	AC	5,811,127	09-22-98	Milstein *et al.*
	AD	5,091,180	02-25-92	Walker et al.

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	TRANSLATION NO
	AL	WO 94/01770 A	01-20-1994	Shapiro, Svetlana Borisovna and Aleksandrovskaya, Tamara Nikolayevna	X	
	AM	DE 40 08 323 A	09-19-1991	Knoll AG	X	
	AN	WO 00/13706 A	03-06-2000	Henry Ford Health System		
	AO	WO 91/07956 A	06-13-1991	Knoll Aktiengesellschaft		X

EXAMINER	DATE CONSIDERED
	02/23/2005

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2629.1003-008
April 8, 2004	FIRST NAMED INVENTOR Sudhir V. Shah
(Use several sheets if necessary)	

		OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*
W	AR	Sumboonnanonda, A., *et al.*, "Renal tubular function in β-thalassemia", *Pediatr Nephrol*, 12:280-283.
~	AS	Ong-ajyooth, L., *et al.*, "Renal Function in Adult Beta-Thalassemia/Hb E Disease", *Nephron*, 78:156-161 (1998).
~	AT	Guasch, A., *et al.*, "Evidence that Microdeletions in the α Globin Gene Protect Against the Development of Sickle Cell Glomerulopathy in Humans", *J Am Soc Nephrol*, 10:1014-1019 (1999).
~	AU	Loebstein, R., *et al.*, "Diabetic Nephropathy in Hypertransfused Patients with β-Thalassemia", *Diabetes Care*, 21(8):1306-1309 (1998).
~	AV	Ongajyooth, L., *et al.*, "Glomerulonephritis in β-thalassemia Hb-E Disease: Clinical Manifestations, Histopathologic Studies and Outcome", *J Med Assoc Thai*, 78(3):119-126 (1995).
~	AW	Aoki, R.Y., *et al.*, "Microalbuminuria in Sickle Cell Disease", *Brazilian J Med Biol Res*, 23:1103-1106 (1990).
~	AX	Katopodis, K.P., *et al.*, "Renal Abnormalities in Patients with Sickle Cell-Beta Thalassemia", *Journal of Nephrology*, 10(3):163-167 (1997).
~	AY	Pham, P.-T.T., *et al.*, "Renal abnormalities in sickle cell disease", *Kidney International*, 57:1-8 (2000).
~	AZ	Kontoghiorghes, G.J., *et al.*, "Simple Synthesis of the Potent Iron Chelators 1-Alkyl-3-hydroxy-2-methylpyrid-4-ones", *Inorganica Chimica Acta.*, 136:L11-L12 (1987).
~	AR2	Falk, R.J., *et al.*, "Prevalence and Pathologic Features of Sickle Cell Nephropathy and Response to Inhibition of Angiotensin-Convertng Enzyme", *The New England Journal of Medicine*, 326(14):910-915 (1992).
~	AS2	Guasch, A., *et al.*, "Sickle cell anemia causes a distinct pattern of glomerular dysfunction", *Kidney International*, 51:826-833 (1997).
~	AT2	Cianciulli, P., *et al.*, "Early detection of nephrotoxic effets in thalassemic patients receiving desferrioxamine therapy", *Kidney International*, 46:467-470 (1994).
~	AU2	Ueda, N., *et al.*, "Role of 'catalytic' iron in an animal model of minimal change nephrotic syndrome", *Kidney International*, 49:370-373 (1996).

EXAMINER	DATE CONSIDERED
[signature]	02/16/2005

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2629.1003-008
April 8, 2004	FIRST NAMED INVENTOR Sudhir V. Shah
(Use several sheets if necessary)	

		OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*
	AV2	Savill, J., *et al.*, "Mechanisms of glomerular injury". In "Oxford Textbook of Clinical Nephrology," 2nd ed., pages 404-439, eds., Davidson, A.M., *et al.*, Oxford Univ. Press (1998).
	AW2	Ueda, N., *et al.*, "*In Vivo* Evidence for a Role of Reactive Oxygen Metabolites in Glomerular Disease", *Kidney: A Current Survey of World Literature*, 6:143-146 (1997).
	AX2	Boyce, N.W., *et al.*, "Hydroxyl radical mediation of immune renal injury by desferrioxamine", *Kidney International*, 30:813-817 (1986).
	AY2	Baliga, R., *et al.*, "Kidney Iron Status in Passive Heymann Nephritis and the Effect of an Iron-Deficient Diet", *J Am Soc Nephrol*, 7(8):1183-1188 (1996).
	AZ2	Shah, S.V., "Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats", *The American Physiological Society*, F337-F344(1988).
	AR3	Thakur, V., *et al.*, "Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria", *Kidney International*, 34:494-499 (1988).
	AS3	Nankivell, B.J., *et al.*, "The Role of Tubular Iron Accumulation in the Remnant Kidney", *J Am Soc Nephrol*, 4(8):1598-1607 (1994).
	AT3	Alfrey, A.C., *et al.*, "Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis", *Kidney International*, 36:753-759 (1989).
	AU3	El Nahas, A.M., "Mechanisms of experimental and clinical renal scarring" In: "Oxford Textbook of Clinical Nephrology", 2nd ed., pages 1749-1788, eds., Davidson, A.M., *et al.*, Oxford Univ. Press (1998).
	AV3	Howard R.L., *et al.*, "Urinary albumin, transferrin and iron excretion in diabetic patients", *International Society of Nephrology*, 40:923-926 (1991).
	AW3	Olivieri, N.F., *et al.*, "Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major", *The New England Journal of Medicine*, 918-922 (1995).
	AX3	Alfrey A.C., "Toxicity of tubule fluid iron in the nephrotic syndrome", *American Journal of Physiology*, 263(4):F637-F641 (1992).

EXAMINER	DATE CONSIDERED
	02/28/2005

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2629.1003-008
April 8, 2004	FIRST NAMED INVENTOR Sudhir V. Shah
(Use several sheets if necessary)	

		OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*
dr	AY3	Wu, Z-L, *et al.*, "Iron Loading Enhances Susceptibility to Renal Ischemia in Rats," *Renal Failure*, 16(4): 471-480 (1994).
dr	AZ3	Baliga, R., *et al.*, "In Vitro and In Vivo Evidence Suggesting a Role for Iron in Cistaplin-induced Nephrotoxicity," *Kidney International*, 53(2): 394-401 (February 1998).
dr	AR4	Harris, D., *et al.*, "Mitrochondrial Function in Rat Renal Cortex in REsponse to Proteinuria and Iron," *Clinical and Experimental Pharmacology and Physiology* 24:916-922 (December 1997).
dr	AS4	Walker, P.D., *et al.*, "Evidence Suggesting a Role for Hydroxyl Radical in Gentamicin-Induced Acute Renal Failure in Rats," *J Clin Invest 81*:334-341 (1988).
dr	AT4	Shah, S.V., *et al.*, "Evidence Suggesting a Role for Hydroxyl Radical in Glycerol-Induced Acute Renal Failure," *Am J Physiol 255, (Renal Fluid Electrolyte Physiol. 24)*:F438-F443 (1988).
dr	AU4	Baliga, R., *et al.*, "Increase in Bleomycin-Detectable Iron in Ischaemia/Reperfusion Injury to Rat Kidneys," *Biochem J 291(3)*:901-905 (1993).
dr	AV4	Kontoghiorghese, G.J., *et al.*, "Studies of Aluminium Mobilization in Renal Dialysis Patients Using the Oral Chelator 1,2-Dimethyl-3-hydroxypyrid-4-one," *Arzneim-Forsh/Drug Res. 44(1)*:522-526 (1994).
dr	AW4	Baliga, R., *et al.*, "Oxidant Mechanisms in Toxic Acute Renal Failure," *Drug Metabolism Reviews 31(4)*:971-991 (1999).
dr	AX4	Walker, P.D., *et al.*, "Gentamicin Enhanced Production of Hydrogen Peroxide by Renal Cortical Mitochondria," *Am J Physiol 253*:C495-C499 (1987).
dr	AY4	Walker, P.D., *et al.*, "Hydrogen Peroxide Cytotoxicity in LLC-PK$_1$ Cells: A Role for Iron," *Kidney Int 40*:891-898 (1991).
dr	AZ4	Abul-Ezz, S.R., *et al.*, "Role of Glutathione in an Animal Model of Myoglobinuric Acute Renal Failure," *Proc Natl Acad Sci 88*:9833-9837 (1991).
dr	AR5	Ueda, N., *et al.*, "Gentamicin-Induced Mobilization of Iron from Renal Cortical Mitochondria," *Am J Physiol 265(3 Pt. 2)*:F435-F439 (1993).
dr	AS5	Baliga, R., *et al.*, "Evidence for Cytochrome P-450 as a Source of Catalytic Iron in Myoglobinuric Acute Renal Failure," *Kidney Int 49*:362-369 (1996).

EXAMINER	DATE CONSIDERED
	01/13/2005

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2629.1003-008
April 8, 2004	FIRST NAMED INVENTOR Sudhir V. Shah
(Use several sheets if necessary)	

		OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*
W	AT5	Baliga, R., *et al.*, "Role of Cytochrome P-450 as a Source of Catalytic Iron in Cisplatin-Induced Nephrotoxicity," *Kidney Int 54*:1562-1569 (1998).
W	AU5	Hanss, B.G., *et al.*, "The Iron Chelator Deferoxamine Prevents Contrast Media Induced Acute Renal Failure in the Rabbit." Presented at the American Society of Nephrology, 23rd Annual Meeting, *JASN 1(4)*:612 (1990) (abstract).
W	AV5	Baliga, R., *et al.*, "Role of Iron in Cisplatin-Induced Acute Renal Failure in Rats," *J Am Soc Nephrol 7(9)*:1822 (1996) (abstract).

EXAMINER	DATE CONSIDERED
	02/09/2005